Beth Fand Incollingo

Articles

With ADT in PC, Managing Side Effects Increasingly Important

July 1st 2014

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

Why Chemotherapy Remains Vital in an Era of Targeted Agents and Immunotherapies

June 20th 2014

When Franco Muggia, MD, was a freshly minted oncologist 50 years ago, his new colleagues warned him not to waste much time learning about a drug like fluorouracil.

Vogelzang Sees Early Chemo Strategy as Landmark Change in Prostate Cancer Therapy

June 10th 2014

Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Novel Imaging Techniques for Metastatic Prostate Cancer Advance

June 9th 2014

Improved imaging modalities are needed to help advance treatment of men diagnosed with metastatic prostate cancer, and several novel techniques are under study

Adjuvant Ipilimumab Reduces Risk of Recurrence in Stage III Melanoma

June 2nd 2014

The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.

Adding Chemo to ADT Confers Dramatic Survival Gains in Prostate Cancer

June 1st 2014

In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.

Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer

May 31st 2014

Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.

Goserelin Preserves Fertility, Aids Survival During Breast Cancer Chemo

May 31st 2014

Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.

Intermittent Degarelix Effective With Less Metabolic Syndrome Than Hormone Agonists, Studies Suggest

May 20th 2014

Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule

In Dog Study, Prostate Cancer Found With a Whiff and a Woof

May 19th 2014

When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.

Social Media Vital in Marketing Large Urology Practices

May 18th 2014

In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.

Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests

May 14th 2014

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

Immediate Surgery Improves Outcomes in Localized Prostate Cancer

May 13th 2014

A recent study that followed men newly diagnosed with localized prostate cancer for a median 18 years found that immediate radical prostatectomy significantly cut death rates as compared with watchful waiting with treatment upon progression, especially in men with intermediate-risk disease.

Studies Challenge Common Treatment Strategies in Prostate Cancer

May 8th 2014

Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis

AGS-003 to Be Tested With Sunitinib as RCC Treatment

May 7th 2014

A trial (NCT01582672) that will pair a targeted treatment with a vaccine therapy for firstline treatment of renal cell carcinoma (RCC) is recruiting at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

Vitamin E, Selenium Can Greatly Increase Prostate Cancer Risk

May 6th 2014

Despite being quite popular, the dietary supplements vitamin E and selenium do not protect men from developing prostate cancer, and in fact greatly increase risk in certain patients if taken at doses higher than those recommended

SABCS Surgical Studies With Practice-Changing Potential Form Basis of Review of Noteworthy Data

May 5th 2014

The value of surgery in some women with metastatic breast cancer was challenged by data from studies presented at the recent San Antonio Breast Cancer Symposium

Downregulated Oncogene Raises OS in Obese Patients With RCC

April 25th 2014

Obesity increases the chance that someone will get the clear-cell form of renal cell carcinoma (ccRCC). But once an obese patient has the disease, he's likely to survive longer than a non-obese patient.

LUGPA Aims to Help Practices Thrive: Leaders Discuss Progress and Goals

April 1st 2014

During the annual meeting of the Large Urology Group Practice Association (LUGPA) in Chicago in November 2013, the organization's president, Deepak A. Kapoor, MD, completed his 2-year term and handed the gavel to incoming president Juan A. Reyna, MD.

Nab-Paclitaxel Therapy in Pancreatic Cancer Deemed Patient Friendly

March 28th 2014

A recently approved indication for nab-paclitaxel (Abraxane) in metastatic pancreatic cancer is thought to have similar efficacy to a standard first-line treatment for the disease, but offers several advantages in the eyes of community oncologists and their patients